High dose dry powder inhalers to overcome the challenges of tuberculosis treatment
| Autor: | Ian G. Tucker, Mohammad A.M. Momin, Shyamal C. Das |
|---|---|
| Rok vydání: | 2018 |
| Předmět: |
Background information
medicine.medical_specialty Tuberculosis Antitubercular Agents Pharmaceutical Science 02 engineering and technology Drug resistance 030226 pharmacology & pharmacy 03 medical and health sciences 0302 clinical medicine Administration Inhalation medicine Animals Humans Intensive care medicine Tuberculosis Pulmonary Asthma COPD business.industry Inhaler Dry Powder Inhalers 021001 nanoscience & nanotechnology medicine.disease Dry-powder inhaler Dry powder 0210 nano-technology business |
| Zdroj: | International Journal of Pharmaceutics. 550:398-417 |
| ISSN: | 0378-5173 |
| Popis: | Tuberculosis (TB) is a major global health burden. The emergence of the human immunodeficiency virus (HIV) epidemic and drug resistance has complicated global TB control. Pulmonary delivery of drugs using dry powder inhalers (DPI) is an emerging approach to treat TB. In comparison with the conventional pulmonary delivery for asthma and chronic obstructive pulmonary disease (COPD), TB requires high dose delivery to the lung. However, high dose delivery depends on the successful design of the inhaler device and the formulation of highly aerosolizable powders. Particle engineering techniques play an important role in the development of high dose dry powder formulations. This review focuses on the development of high dose dry powder formulations for TB treatment with background information on the challenges of the current treatment of TB and the potential for pulmonary delivery. Particle engineering techniques with a particular focus on the spray drying and a summary of the developed dry powder formulations using different techniques are also discussed. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect